This article is more than 5 years old. Information may no longer be current.
VIDEO: CT-derived FFR shows promise in suspected ACS, warrants further investigation
Click Here to Manage Email Alerts
CHICAGO — Maros Ferencik, MD, PhD, of the Oregon Health & Science University in Portland, offers investigator insight on non-invasive fractional flow reserve measurements in patients with symptoms suggestive of ACS from the ROMICAT II trial, comparing early coronary CT angiography as part of initial ED evaluation vs. standard evaluation.
He provides context for the research by highlighting promising safety and efficacy findings with CTA in this population from the large NHLBI- and NIH-sponsored trial as well as recent observations on FFR when measured invasively vs. non-invasively, then goes on to detail three main findings from the current investigation.
Ferencik points to 1-year results from the PLATFORM study by Pamela S. Douglas, MD, of Duke Clinical Research Institute and Duke University School of Medicine, as offering further support for the use of CT-derived FFR in the setting of chest pain.
“This all puts into perspective that we need in the future to evaluate FFRCT prospectively in patients with both acute chest pain and stable chest pain,” he said. “This is a chance for further work with FFRCT and for coronary CTA.”